Related Experiment Video
Updated: Jun 18, 2025
08:09
Echocardiographic Assessment of Cardiac Anatomy and Function in Adult Rats
Published on: December 13, 2019
21.0K
Left ventricular diastolic dysfunction in patients with heart failure with mildly reduced ejection fraction
Noah Abel1, Tobias Schupp1, Alexander Schmitt1
1Department of Cardiology, Angiology, Haemostaseology and Medical Intensive Care, University Medical Centre Mannheim, Medical Faculty Mannheim, Heidelberg University, 68167 Mannheim, Germany.
International Journal of Cardiology
|July 30, 2024
Summary
Diastolic dysfunction (DD) is common in heart failure with mildly reduced ejection fraction (HFmrEF), affecting 72% of patients. However, this study found DD does not impact long-term mortality or rehospitalization risk in HFmrEF patients.
Area of Science:
- Cardiology
- Internal Medicine
- Heart Failure Research
Background:
- Limited data exists on the prognostic significance of diastolic dysfunction (DD) in heart failure with mildly reduced ejection fraction (HFmrEF).
- Understanding DD's impact is crucial for risk stratification and management of HFmrEF patients.
Purpose of the Study:
- To determine the prevalence of diastolic dysfunction (DD) in hospitalized patients with heart failure with mildly reduced ejection fraction (HFmrEF).
- To investigate the prognostic impact of DD on all-cause mortality and rehospitalization for worsening HF in this population.
Main Methods:
- Retrospective analysis of 1154 hospitalized HFmrEF patients (LVEF 41-49%) from 2016-2022.
- Patients were categorized based on the presence and severity of diastolic dysfunction (DD).
- Primary endpoint: all-cause mortality at 30 months; secondary endpoint: HF rehospitalization.
Main Results:
- Diastolic dysfunction (DD) was prevalent in 72% of HFmrEF patients, who were older and had more comorbidities.
- The presence or severity of DD was not associated with increased risk of all-cause mortality or HF rehospitalization.
- Adjusted HR for mortality was 0.815 (p=0.161) and for HF rehospitalization was 0.736 (p=0.238) in patients with DD.
Conclusions:
- Diastolic dysfunction (DD) is highly prevalent in patients hospitalized with heart failure with mildly reduced ejection fraction (HFmrEF).
- Despite its high prevalence, DD is not associated with adverse long-term prognosis in terms of mortality or rehospitalization in HFmrEF patients.
Related Concept Videos
01:17Pathophysiology of Heart Failure
1.5K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.5K
01:26Imbalances in Cardiac Output
1.4K
The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
1.4K
01:22Heart Failure Drugs: Diuretics
355
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
355
01:22Heart Failure Drugs: β-Blockers
332
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
332
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
413
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
413